Faeth Therapeutics (FTH)
NASDAQ:FTH
Want to see FTH full AI Analyst Report?
Total Valuation
Faeth Therapeutics has a market cap or net worth of $23.91M. The enterprise value is -$128.96M.
Market Cap$23.91M
Enterprise Value-$128.96M
Share Statistics
Faeth Therapeutics has 1,341,941 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,341,941
Owned by Insiders53.09%
Owned by Institutions2.69%
Financial Efficiency
Faeth Therapeutics’s return on equity (ROE) is -1.13 and return on invested capital (ROIC) is -110.88%.
Return on Equity (ROE)-1.13
Return on Assets (ROA)-0.92
Return on Invested Capital (ROIC)-110.88%
Return on Capital Employed (ROCE)-1.20
Revenue Per Employee0.00
Profits Per Employee-727.07K
Employee Count29
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Faeth Therapeutics is ―. Faeth Therapeutics’s PEG ratio is -0.00049.
PE Ratio―
PS Ratio0.00
PB Ratio0.72
Price to Fair Value0.72
Price to FCF-0.66
Price to Operating Cash Flow-0.96
PEG Ratio-0.00049
Income Statement
In the last 12 months, Faeth Therapeutics had revenue of 0.00 and earned -21.09M in profits. Earnings per share was -16.72.
Revenue0.00
Gross Profit0.00
Operating Income-22.29M
Pretax Income-21.09M
Net Income-21.09M
EBITDA-20.91M
Earnings Per Share (EPS)-16.72
Cash Flow
In the last 12 months, operating cash flow was -24.09M and capital expenditures -22.00K, giving a free cash flow of -24.11M billion.
Operating Cash Flow-24.09M
Free Cash Flow-24.11M
Free Cash Flow per Share-17.97
Dividends & Yields
Faeth Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.77
52-Week Price Change132.64%
50-Day Moving Average22.11
200-Day Moving Average16.41
Relative Strength Index (RSI)51.69
Average Volume (3m)38.93K
Important Dates
Faeth Therapeutics upcoming earnings date is Aug 11, 2026, Before Open (Confirmed).
Last Earnings DateMay 15, 2026
Next Earnings DateAug 11, 2026
Ex-Dividend Date―
Financial Position
Faeth Therapeutics as a current ratio of 5.06, with Debt / Equity ratio of 0.54%
Current Ratio5.06
Quick Ratio5.06
Debt to Market Cap0.00
Net Debt to EBITDA0.34
Interest Coverage Ratio-696.50
Taxes
In the past 12 months, Faeth Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Faeth Therapeutics EV to EBITDA ratio is -0.30, with an EV/FCF ratio of -0.31.
EV to Sales0.00
EV to EBITDA-0.30
EV to Free Cash Flow-0.31
EV to Operating Cash Flow-0.31
Balance Sheet
Faeth Therapeutics has $202.79M in cash and marketable securities with $1.04M in debt, giving a net cash position of $201.75M billion.
Cash & Marketable Securities$202.79M
Total Debt$1.04M
Net Cash$201.75M
Net Cash Per Share$150.34
Tangible Book Value Per Share$14.75
Margins
Gross margin is 2740.82%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin2740.82%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Faeth Therapeutics is $53.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$53.33
Price Target Upside367.02% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast―
EPS Growth Forecast-518.34%